Comparison of plasma endothelin levels between osteoporotic, osteopenic and normal subjects by Muratli, Hasan Hilmi et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
BMC Musculoskeletal Disorders
Open Access Research article
Comparison of plasma endothelin levels between osteoporotic, 
osteopenic and normal subjects
Hasan Hilmi Muratli*, Levent Çelebi, Onur Hapa and Ali Biçimoğlu
Address: 3rd Orthopaedics and Traumatology Clinic, Ankara Numune Education and Research Hospital, Talatpas ¸a Bulvarı, Sıhhiye, Ankara, Turkey
Email: Hasan Hilmi Muratli* - hasanmuratli@yahoo.com; Levent Çelebi - leventcelebi@superonline.com; Onur Hapa - hapajan@hotmail.com; 
Ali Biçimoğlu - bicimoglu@hotmail.com
* Corresponding author    
Abstract
Background: It has been demonstrated that endothelins (ET) have significant roles in bone
remodeling, metabolism and physiopathology of several bone diseases. We aimed to investigate if
there was any difference between the plasma ET levels of osteoporotic patients and normals.
Methods: 86 patients (70 women and 16 men) with a mean age of 62.6 (ranges: 51–90) years were
included in this study. Patients were divided into groups of osteoporosis, osteopenia and normal
regarding reported T scores of DEXA evaluation according to the suggestions of World Health
Organization. According to these criteria 19, 43 and 24 were normal, osteopenic and osteoporotic
respectively. Then total plasma level of ET was measured in all patients with monoclonal antibody
based sandwich immunoassay (EIA) method. One-way analysis of variance test was used to
compare endothelin values between normals, osteopenics and osteoporotics.
Results: Endothelin total plasma level in patients was a mean of 98.36 ± 63.96, 100.92 ± 47.2 and
99.56 ± 56.6 pg/ml in osteoporotic, osteopenic and normal groups respectively. The difference
between groups was not significant (p > 0.05).
Conclusion:  No significant differences in plasma ET levels among three groups of study
participants could be detected in this study.
Background
The endothelins (ET) are a family of 21-aminoacid pep-
tides consisting of endothelin-1 (ET-1), the related pep-
tides ET-2 and ET-3 [1]. In addition to being among the
most potent vasoconstrictor agents known, ET have been
found to possess a wide range of pharmacological activi-
ties on different tissues [1-3]. The close proximity of cells
on the bone surface to vascular endothelial cells exposes
bone cells to endothelial cell products such as the
polypeptide ET. It is well recognized that ET play an
important role in bone metabolism [4-8].
The receptors for ET on the osteoclasts, osteoblasts and
their intracellular signal systems were predominantly
found out by detailed in vitro and in vivo studies [3,8,9].
ET-A and ET-B receptor subtypes are expressed in bone
cells. Stimulation of phospholipids turnover and activa-
tion of tyrosine kinases are used by ET as a major way
while transducting the intracellular signals [3,9]. It was
also demonstrated that osteoblasts, osteoclasts and osteo-
cyts contain measurable amount of ET [10,11].
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It was shown that ET regulates bone blood flow in the
intact vascularized bone preparations [12]. However ETs'
effects are not limited with their vasoactivity in the bone
tissue. ET stimulates proliferation of the capillary
endothelial cells [2,13-15], osteoblasts and osteoprogeni-
tor cells [3,16]. They also stimulate differentiation of oste-
oprogenitor cells to osteoblasts [3,4,6].
Osteoblastic activity is increased by ET as this effect is
demonstrated by stimulation of synthesis of collagen and
non-collagen proteins [6] as well as osteocalcin and oste-
opontin messages in bone tissue [17].
It was demonstrated that ET has also certain interactions
with 1,25 dihydroxyvitamin D3. Upon in vitro observa-
tions it has been addressed that ET together with vascular
endothelial growth factor (VEGF) and 1,25 dihydroxyvita-
min D3 may have an in vivo activity on bone formation
and remodeling process [7].
There are some controversial reports regarding the effects
of ET on bone resorption. They clearly inhibit motile proc-
ess of the osteoclasts [5,8]. Osteoclastic bone resorption is
inhibited by ET with similar doses that produce vasocon-
striction [5]. Furthermore ET inhibits parathyroid hor-
mone secretion in the parathyroid adenoma cells [18].
However along with these antiresorptive effects it was
shown that they lead to prostaglandin (PG) [19,20] and
interleukin-6 (IL-6) [21] related stimulation of resorption.
There are also controversial reports about ET effects on the
mineralization process of bone. It is thought that miner-
alization is inhibited by ET through the stimulation of ET-
A receptor [22,23]. On the contrary blockage of ET-A
receptors are reported to cause osteopenia in experimental
studies [24].
In the basis of above mentioned effects of ET in the bone,
we thought that ET may have an important role in the
physiopathology of osteoporosis and according to our
investigation there is no epidemiologic study available in
the literature, in particular to investigate the associations
between ET and bone mineral density. We aimed to find
out if there was any difference of the ET plasma levels
between osteoporotic and normal people.
Methods
Groups of patients
242 patients who were over 50 years of age were referred
by us to examine in our hospital's radiology department
just for screening by dual energy X-ray absorbsiometry
(DEXA) during from March to June 2004 were invited to
the present study as soon as the results of DEXA were
obtained. Patients with systemic diseases (diabetes,
hypertension, renal disease, or clinical manifestation of
atherosclerosis or known another diseases) and patients
with abnormal laboratory results (regarding routine
hemogram parameters and routine biochemical test) were
planned to excluded. Other exclusion criteria were
receival of any medication for osteoporosis previously or
another drug in the last 3 months before the study and
smoking or drinking alcoholic beverages for at least 48
hours before the blood sample receival. Presence of any
anamnestic or clinical signs of osteoporosis (pain and pre-
vious fractures) and presence of any differences from ref-
erence values of the biochemical markers of bone
remodeling in the patients with normal bone density
according to our accepted criteria described below was
accepted as another exclusion criteria.
The study was performed cross-sectionally. After first
interview 12 of 242 invited patients refused to participate
in the study. 44 patients who had known systemic dis-
eases (diabetes, hypertension, renal disease, or clinical
manifestation of atherosclerosis) and 22 patients who had
received drugs in the last 3 months before the study were
excluded at the beginning. 24 patients who received any
treatment for osteoporosis before the study were also
excluded. 16 participants who were evaluated as normal
regarding bone mineral densitometry evaluation but who
had any anamnestic or clinical signs of osteoporosis (pain
and previous fractures) were also excluded from the study.
Remaining 124 patients who accepted to join our study
were informed of the nature of the study. Consent was
obtained from each participant. Then all patients were
analyzed on clinical and biochemical basis. Then systemic
blood pressures were measured in all other participants
and 16 patients were excluded because of high blood
measurement. Then Complete blood count and biochem-
ical profiles including routine biochemical tests and bio-
chemical markers of bone remodeling were assessed and
20 patients were excluded because of the pathological
findings in this analysis. Although they were instructed
not to use, 2 patients who smoked or drank alcoholic bev-
erages in the period of 48 hours before the blood sample
collection were excluded from the study.
At the end of these initial evaluation procedures remain-
ing 86 patients were included in this study according to
our accepted criteria. There were 16 males and 70 females.
Mean age was 62.6 (ranges: 51–90) years. Patients were
divided into 3 groups regarding reported T scores in DEXA
evaluation. Consistent data base regarding young normal
value and the population standard deviation were used in
order to calculate T score. T-scores less than -2.5 on either
total lumbar spine or total hip were accepted as oste-
oporosis, while scores between -1 and -2.5 were accepted
as osteopenia and scores above -1 were accepted as nor-
mal according to the suggestions of World HealthBMC Musculoskeletal Disorders 2005, 6:49 http://www.biomedcentral.com/1471-2474/6/49
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Organization (WHO) [25]. According to suggested criteria
of WHO [25] 19 of 86 were normal, 43 were osteopenic
and 24 were osteoporotic. All patients' demographic and
anthropometrical characteristics were noted.
Methods
After the insertion of a teflon cannula into the antecubital
vein all subjects remained recumbent for at least 30 min-
utes. Then 5 ml of venous blood was withdrawn in vacu-
tainer K2-EDTA plasma tubes from all patients 8 hours
after overnight fasting. Blood samples were centrifuged
immediately for 15 minute at 2000 × g. Then plasma sam-
ples were stored frozen at -80°C until EIA.
We had quantified the total amount of human ET fasting
plasma level by using commercially available Endothelin-
1 EIA (Endothelin EIA Kit, Catalog No:583151, Cayman
Chemical Company, Michigan, USA) following instruc-
tions of the manufacturer. This immunometric assay is
based on a double-antibody 'sandwich' technique and
permits endothelin measurements within the range of 0–
250 pg/ml, typically with a limit of detection of 1,5 pg/ml.
Monoclonal anti ET-1 antibody in this kit had a cross reac-
tivity of 100% with ET-2 and 100% with ET-3. Samples
were assessed with no prior purification.
The intra- and inter-assay coefficients of variation of the
method were 5 and 6%, respectively.
In this method monoclonal antibody specific to endothe-
lin and acetylcholinesterase: Fab' Conjugate (AChE:Fab')
bind to different epitopes on the Endothelin-1 molecule
and forming sandwich. This sandwich is immobilized on
the plate so the excess reagents are washed away. The con-
centration of analyte is detected by measuring the enzy-
matic activity of the AChE by adding Ellman's Reagent
which contains the substrate for AChE. Addition of Ell-
man's Reagent produces a yellow-colored product which
can be measured spectrophotometrically. The intensity of
the color is directly proportional to the amount of bound
conjugate which in turn is proportional to the concentra-
tion of the Endothelin.
Enzyme immunometric analysises were run twice from
the same sample (in Düzen Laboratories Chain, Ankara,
Turkey).
Data analysis
Data analyses were done by SPSS for Windows version
11.5. Prior to the analysis, all the data were examined for
accuracy of data entry and fit between their distributions
and the assumptions of univariate analysis. To improve
pairwaise linearity and to reduce the extreme skewness
and kurtosis, the z score for all variables was computed. It
was found that all dependent variables are normally
distributed.
Data was analyzed using two-way analysis of variance
(two-way ANOVA) to assess statistical significance. Inde-
pendent variables were group of subject (osteoporotics,
osteopenics and normals), and gender (male and female);
dependent variable was endothelin value.
This analysis was also used to compare weight, height and
body mass index parameters between the groups of
subjects.
By using the formula y = y'-b.(x-x') (y: new endothelin, y':
old endothelin, b: regression coefficient x: weight or
height or body mass index or age, x': mean weight or
height or body mass index or age) we had made endothe-
lin independent of weight, height and body mass index
because these variables were treated as covariate variables.
Osteoporotics, osteopenics and normals were compared
for statistical significance in terms of endothelin levels
using one-way ANOVA test after controlling for covari-
ates. Two-way ANOVA test was used to confirm the differ-
ence of endothelin level between the males and females
for each group separately after controlling for covariates.
A value of p < 0.05 was considered as significant.
Pearson Product Moment Correlation coefficient analysis
was used to detect relation between age, body mass index,
height, weight, T scores and endothelin levels. All values
were given as mean ± S.D.
Results
Age, gender and anthropometrical parameters of the
groups were summarized in Table 1.
Average systemic blood pressure of study participants was
126 ± 8 (Mean ± S.D.) mmHg and 75 ± 9 mmHg for systo-
lic and diastolic levels.
Endothelin fasting plasma levels
Endothelin fasting plasma levels were found comparable
in both runs of analysises. Unadjusted ET total plasma lev-
els were a mean of 98.36 ± 63.96 pg/ml in osteoporotic
group, a mean of 100.92 ± 47.2 pg/ml in osteopenic
group and a mean of 99.56 ± 56.6 pg/ml in normal group.
The difference between groups was not significant. (p >
0.05) (Figure 1)
Levels according to gender
In men with osteoporosis mean unadjusted ET level was
185.7 ± 17.2 pg/ml and this was significantly higher than
in osteopenic men (124.8 ± 59.6 pg/ml) and in normal
men (93.0 ± 50.1 pg/ml) (p < 0.05). In women there was
not any significant difference between groupsBMC Musculoskeletal Disorders 2005, 6:49 http://www.biomedcentral.com/1471-2474/6/49
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(normal:102.0 ± 60.7 pg/ml, osteopenics: 94.7 ± 42.7 pg/
ml, osteoporotics: 79.9 ± 53.8 pg/ml, p > 0.05). (Figure 1)
Independent of osteoporotic status mean ET level was sig-
nificantly higher in men (130.1 ± 58.7 pg/ml) than
women (91.5 ± 50.2 pg/ml). (p < 0.05)
In osteoporotics mean ET level was significantly higher in
men than in women. (p < 0.001). In osteopenic men
mean ET level was higher than women but it was not sig-
nificant (p > 0.05). In normal group mean ET level was
lower in men than in women but it was not significant too
(p > 0.05).
Levels according to age
When adjusted to age, ET levels did not differ significantly
between groups. (p > 0.05)
Levels according to anthropometrical parameters
Osteoporotics had significantly lower values of weight
than normals and osteopenics. (p < 0.001) Osteoporotics
were significantly shorter than normals and osteopenics.
(p < 0.05) As a result of these osteoporotics had signifi-
cantly lower body mass index than normals and osteo-
penics. (p < 0.01)
After separately adjustments to body weight, length and
body mass index, ET levels did not differ significantly
between groups. (p > 0.05)
Regardless of groups there was no significant correlation
between neither weight nor height and ET values. (p >
0.05)
In normal groups no correlation was found between
weight, length, body mass index and ET levels. (p > 0.05)
In osteopenic patients we have found negative correlation
of weight (r:-0.36, p < 0.05), body mass index (r:-0.45, p
< 0.01) and ET values. In osteoporotics we have found
positive correlation of height and ET levels. (r:0.41, p <
0.05)
Other correlation studies
Regardless of groups and in osteopenics and osteoporotics
there was no correlation between vertebral or hip T scores
and ET values (p > 0.05) but a correlation between hip T
scores and ET values of normal group (r:-0.5, p < 0.05).
Discussion
After demonstration of ETs' important effects on bone tis-
sue it was begun to be considered that they may have cer-
tain roles in the physiopathology of some clinical entities
[26,27]. As a matter of fact Tarquini et al. measured the
circulating ET-1 levels of patients with Paget Disease in
which the bone turn over is extremely increased and they
found out that ET-1 level was significantly increased in
patients with Paget Disease when compared to controls
[27]. So they believed that ET-1 may have a role in the
Table 1: Demographical and anthropometrical characteristics of the groups.
Number of 
cases
Gender Age (years) 
Mean ± S.D.
Height (cm) 
mean ± S.D.
Weight (kg) 
mean ± S.D.
BMI (kg/m2) 
mean ± S.D.
MF
Osteoporotics 24 4 20 65.95 ± 9.4a 153.29 ± 7.69b 65.79 ± 12.4c 28.02 ± 5.14a
Osteopenics 43 7 36 62.60 ± 7.9 156.09 ± 6.48 75.90 ± 11.72 31.19 ± 4.68
Normal 19 5 14 58.20 ± 7.6 160.0 ± 13.27 83.15 ± 11.5 33.01 ± 6.61
a: There is a significant difference between normals, osteopenics and osteoporotics (p < 0.01)
b: There is a significant difference between normals, osteopenics and osteoporotics (p < 0.05)
c: There is a significant difference between normals, osteopenics and osteoporotics (p < 0.001)
Plasma ET levels (mean ± S.D.) before the adjustments for  age, weight and height of each group are presented  diagrammatically Figure 1
Plasma ET levels (mean ± S.D.) before the adjustments for 
age, weight and height of each group are presented 
diagrammatically.
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physiopathology of this disease and it could be used as a
marker.
We investigated if ET had a role in the physiopathology of
osteoporosis. We found out that comparison regardless of
gender among osteoporotics, osteopenics and normals
and comparison of female osteoporotics, osteopenics and
normals yielded no significant differences regarding
plasma ET levels. In addition regardless of groups (accord-
ing to suggested criteria of WHO [25]) no correlation was
found between vertebral or hip T scores and ET values.
Although plasma ET levels of osteoporotic men were
found significantly higher than normal men we believed
that it could be speculative to make conclusion with these
findings because there were only 4 osteoporotic men in
the series.
Studies about the men osteoporosis demonstrated us that
although total estradiol levels do not change substantially
over life in men, bioavailable estradiol levels decrease to
50% of the levels in young men in the older ages. It is
thought that this decline in bioavailable estradiol levels
may be the major cause of bone loss in elderly oste-
oporotic men [28,29]. In previous laboratory studies it
was shown that estrogens down regulated ET-1 both
through the secretion from the vascular endothelial cells
and m-RNA expression levels [30,31]. Upon these obser-
vations we believed that possible reason for higher plasma
ET levels of osteoporotic men then the normal men in our
study may be because of the lower bioavaliable estrogen
concentration of the males in these ages and as a result
possible decrease of estrogens effect in down regulation in
ET and consequently increase of ET amount and effects. In
fact bone loss is more accelerated in women after meno-
pause as a result of a decline in circulating estrogens levels
then the men in the same ages period [32]. However con-
sidering presence of no difference in the plasma ET levels
between the osteoporotics, osteopenics and normals in
the women population of our study participants it is not
possible to say same mechanism is true for women regard-
ing the ET and estrogens interaction.
Regarding osteoporosis physiopathology there are many
effects of ET which can cause bone resorption and inhibi-
tion on the mineralization process as follows. ET-1's effect
through the PG system [19,20] and IL-6 expression [21]
are in favor of stimulating bone resorption. Recently it
was described that expression of mRNA of PG endoperox-
ide G/H synthase is stimulated by ET-1 and this stimula-
tion is a way of leading increase of PGE-2 production [20].
Tatrai and Stern [19] showed that ET-1 modulates the
intracellular calcium signalization of PGE-1 and if the
cells confronts with ET-1 then PGE-1 comes out. As a
result ET-1 causes bone resorption depended with PGs.
Hierl et al. [21] showed that ET-1 has a dose dependent
stimulatory effect on IL-6 expression in human osteblastic
cell (HOC) cultures. IL-6 leads to bone resorption
potently and it's this action was described with detailed in
vivo and in vitro studies. And ET-1s' bone resorptive effect
in the cell culture environment was mainly attributed to
its effect on the IL-6 expression stimulation.
There are also reports about inhibitory activity of ET on
the mineralization process of bone. Hiruma et al. [22]
demonstrated that calcium deposition into the bone cells
is decreased by ETs in rat calvarial osteoblast like cell cul-
tures. They concluded that mineralization process in the
osteoblasts may be inhibited by ET-1 through the ET-A
receptor. Inoue et al. [23] also reported similar findings.
Considering findings of reports cited above which are in
favor of ET's stimulatory effect on bone resorption and
inhibitory effects on the mineralization process on bone
tissue we thought ET can be the important peptide in the
osteoporosis physiopathology and we thought we can
find differences in the plasma ET levels between oste-
oporotics and normal subjects. But our findings do not
support this idea.
According to manufacturer's instructions normal levels of
ET-1 in human plasma are below the detection limit of the
kit which we used; therefore purification and concentra-
tion of the sample is necessary for accurate measurement
of ET-1 levels. Considering 100% cross reactions of this kit
for all ET subtypes including ET-1, ET-2 and ET-3 and per-
forming our analysis without prior purification process it
should be addressed that our measurements reflects total
endothelin measurements, not ET-1 alone. We did not
perform purification because manufacturer states that
samples can be assayed with no prior purification in
general and they suggest performing purification process
only for samples containing low concentration of
endothelin (0–50 pg/ml). They also state that samples
must be >50 pg/ml in order to be assayed accurately with
this kit and all average ET levels of our groups was already
in this range. In addition all samples obtained from both
normals and pathologics regarding bone densitometric
evaluation were evaluated with the same method, without
prior purification, and all obtained measurements were
within the detection range of this kit (0–250 pg/ml). So
we believe that in the evaluation of our results and com-
parison of these findings with other studies these points
should be taken into consideration.
Our study has certain limitations. Firstly a number of
study participants were relatively small because oste-
oporosis is a complex disease, known to be affected by
many factors such as age, gender, adiposity, menopause
etc. We believe that subsequent studies should be per-BMC Musculoskeletal Disorders 2005, 6:49 http://www.biomedcentral.com/1471-2474/6/49
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formed with larger number of participants especially for
men. In addition although we only included patients with
no known disease and with normal laboratory findings in
the routine evaluation tests and normal blood pressure, it
was not possible to know with this limited evaluations if
these patients had any disease which are not possible to
diagnose with our screening tests for this study and which
may also cause changes of plasma ET level as mentioned
and referenced below.
Although it is known by many studies that [27,33,34]
increased level of ET concentrations can be detected in the
plasma as a result of overproduction of ET released from
pathologic tissues and/or due to hypervascularization
associated with the lesion in osseous or non-osseous
pathologies, it can be thought that systemic circulation
may thus not entirely reflect local changes in the bones. So
in the substantial studies ET concentrations at the site of
osteoporotic bone tissue should also be evaluated by
biopsies.
Conclusion
According to our findings there is no significant difference
between the ostoeporotics, osteopenics and normals
regarding plasma ET levels. We think that particularly
estrogens, prostaglandins and interleukin levels should
also be measured in similar study designs in order to dis-
cuss the role of ET in osteoporosis and the difference of ET
levels between males and females.
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